Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Access partners to exploit CobaCyte and CobOral technology for targeted RNAi therapeutic delivery

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has entered into an agreement with a major player in RNAi industry to exploit its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.

9 Nov 2011

New breast and ovarian cancer vaccine in the pipeline: Study

A new vaccine is being tried clinically to combat tumor cells in a small study of advanced breast and ovarian cancer patients. The results show that there is improvement in overall survival times and stopping the disease for a handful of breast cancer patients.

8 Nov 2011

Perry's health benefits noted; Romney and Perry spar on immigrants and health care

Texas Gov. Rick Perry is entitled to a lucrative pension from his government job that includes lifetime health care paid for by the state, The Texas Tribune reports. Meanwhile, Perry and former Mass. Gov. Mitt Romney exchanged barbs about their records.

8 Nov 2011

EpiCept reports net loss of $5.4 million for third quarter 2011

EpiCept Corporation today announced operating and financial results for the three and nine months ended September 30, 2011, and provided an update with respect to the Company's key business initiatives.

8 Nov 2011

Just couple of glasses of wine a day could raise risk of breast cancer: Study

According to a new major study just two glasses of a wine a day can increase the risk of breast cancer among women by 50%. Researchers also warn that women who drink regularly in their 20s and 30s are far more likely to develop breast cancer in later life, regardless of whether they reduce their alcohol consumption.

7 Nov 2011

Prostate cancer drug market forecast to grow from $3.6 billion in 2010 to $10.1 billion in 2020

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the launches of several promising emerging therapies, the prostate cancer drug market will experience robust growth over the next decade, increasing from $3.6 billion in 2010 to $10.1 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

7 Nov 2011

Blocking APE1 enzyme could provide new way to kill cancer cells

BLOCKING a key DNA damage repair enzyme, called APE1, could provide a new way to kill cancer cells containing faulty BRCA genes, according to research presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.

7 Nov 2011

Sitting around could be waiting for cancer to strike say researchers

A new analysis reveals that more than 90,000 new cancer cases a year in the United States may be due to physical inactivity and prolonged periods of sitting. The researchers presented their findings at the annual conference of the American Institute for Cancer Research (AICR) in Washington, D.C., citing about 49,000 cases of breast cancer and 43,000 of colon cancer from over 200 studies worldwide.

6 Nov 2011

Cancer drug shortage relates to economics

A perspective in this week's New England Journal of Medicine outlines this connection. Meanwhile, a House Democrat ramps up his investigation into the "gray market" and how it is contributing to the shortage.

4 Nov 2011

Breast cancer not 100% inherited: Study

According to study results released this Monday, women with a close relative with breast cancer may not be at a higher risk of getting breast cancer. The findings may bring comfort to women from high-risk families after a 2007 study suggested that simply having a relative with a BRCA1 or BRCA2 mutation raised their risk of developing breast cancer, even if they had tested negative for the genes.

1 Nov 2011

Senior Scientific's nanomagnetic technology more sensitive in detecting breast cancer

Manhattan Scientifics announced today that "Breast Cancer Research," an international, peer-reviewed online journal, has published results of a study using Senior Scientific's nanomagnetic technology.

1 Nov 2011

Non-carriers do not have increased risk of breast cancer due to familial mutation

A population-based analysis of more than 3,000 families including women with breast cancer has found that close relatives of women who carry mutations in a BRCA gene - but who themselves do not have such genetic mutations - do not have an increased risk of developing breast cancer compared to relatives of women with breast cancer who do not have such mutations.

1 Nov 2011

Fat cells play a major role in mediating ovarian cancer metastasis

A large pad of fat cells that extends from the stomach and covers the intestines provides nutrients that promote the spread and growth of ovarian cancer, reports a research team based at the University of Chicago in the journal Nature Medicine, published online October 30th, 2011.

31 Oct 2011

Infertility treatment linked to borderline ovarian tumors

New research shows that women who undergo ovarian stimulation to produce extra eggs for in-vitro fertilization (IVF) are at increased risk for a type of growth known as “borderline ovarian tumors”.

30 Oct 2011

Ovarian cancer patients with many folate receptors benefit from new therapy

A new strategy that takes advantage of ovarian cancer's reliance on folate appears to give relapse patients extra months of life with few side effects, researchers say.

29 Oct 2011

BROCA test identifies 12 gene mutations linked to ovarian and related cancers

More patients with ovarian carcinoma carry cancer-predisposing mutations, and in more genes, than previously thought.

27 Oct 2011

Taking the Pill for 10 years can reduce risk of ovarian cancer by almost half

Taking the Pill for 10 years can reduce the risk of ovarian cancer by almost half (45 per cent), new research part-funded by Cancer Research UK shows today.

27 Oct 2011

Top-line results from Exelixis' cabozantinib phase 3 trial on medullary thyroid cancer

Exelixis, Inc. today reported top-line results from the ongoing phase 3 clinical trial of cabozantinib in patients with advanced medullary thyroid cancer (MTC), known as the EXAM trial.

24 Oct 2011

Women to benefit from new TFRI ovarian cancer initiative

Women throughout the world will benefit from a new, pan-Canadian Terry Fox Research Institute (TFRI) initiative that aims to change the way in which ovarian cancer is diagnosed and managed.

14 Oct 2011

Manhattan Scientifics' nano-electromagnetic sensing technology can detect MRD in leukemia

Manhattan Scientifics announced today that the National Cancer Institute (NCI) has funded a grant for its Senior Scientific, LLC unit, for the use of its proprietary, highly precise magnetic cancer cell measurement in leukemia research for determining the progress of cancer treatment.

14 Oct 2011